These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38318283)

  • 1. Long-Term Follow-Up of a Case of Severe Hyperglycemia Requiring Hospitalization after Third Dose of Teprotumumab: A Case Report.
    Mehta P; Angell T; LeTran V; Lin M; Nguyen A; Zhang-Nunes S
    Case Rep Ophthalmol; 2024; 15(1):115-121. PubMed ID: 38318283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Case of Hyperglycemic Hyperosmolar State After the Use of Teprotumumab in a Patient With Thyroid Eye Disease.
    Shah K; Charitou M
    AACE Clin Case Rep; 2022; 8(4):148-149. PubMed ID: 35959086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of rapidly declining glycemic control and diabetic ketoacidosis in a newly diagnosed diabetes patient after starting teprotumumab for thyroid eye disease.
    Carter C; Marks M; Bundeff AW; Adewodu T; Alderman L
    Endocrine; 2024 Jan; 83(1):65-68. PubMed ID: 37725291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycemic Trends in Patients with Thyroid Eye Disease Treated with Teprotumumab in 3 Clinical Trials.
    Smith TJ; Cavida D; Hsu K; Kim S; Fu Q; Barbesino G; Wester ST; Holt RJ; Bhattacharya RK
    Ophthalmology; 2024 Jul; 131(7):815-826. PubMed ID: 38253291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus.
    Kuzuya T; Nakagawa S; Satoh J; Kanazawa Y; Iwamoto Y; Kobayashi M; Nanjo K; Sasaki A; Seino Y; Ito C; Shima K; Nonaka K; Kadowaki T;
    Diabetes Res Clin Pract; 2002 Jan; 55(1):65-85. PubMed ID: 11755481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teprotumumab-Related Hyperglycemia.
    Amarikwa L; Mohamed A; Kim SH; Kossler AL; Dosiou C
    J Clin Endocrinol Metab; 2023 Mar; 108(4):858-864. PubMed ID: 36300333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
    Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Report of the committee on the classification and diagnostic criteria of diabetes mellitus.
    ; Seino Y; Nanjo K; Tajima N; Kadowaki T; Kashiwagi A; Araki E; Ito C; Inagaki N; Iwamoto Y; Kasuga M; Hanafusa T; Haneda M; Ueki K
    J Diabetes Investig; 2010 Oct; 1(5):212-28. PubMed ID: 24843435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease.
    Toro-Tobon D; Rachmasari KN; Bradley EA; Wagner LH; Tooley AA; Stokken JK; Stan MN
    Thyroid; 2023 Oct; 33(10):1237-1244. PubMed ID: 37515425
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and Safety of Teprotumumab in Thyroid Eye Disease.
    Teo HM; Smith TJ; Joseph SS
    Ther Clin Risk Manag; 2021; 17():1219-1230. PubMed ID: 34858025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
    Ugradar S; Kossler AL; Douglas R; Cockerham K
    J Neuroophthalmol; 2022 Mar; 42(1):26-34. PubMed ID: 35500236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly Growth Hormone (Lonapegsomatropin) Causes Severe Transient Hyperglycemia in a Child with Obesity.
    Alkhatib EH; Dauber A; Estrada DE; Majidi S
    Horm Res Paediatr; 2023; 96(5):542-546. PubMed ID: 37015214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness of continuous subcutaneous insulin pumps with continuous glucose monitoring in outpatient adolescents with type 1 diabetes: A systematic review.
    Matsuda E; Brennan P
    JBI Libr Syst Rev; 2012; 10(42 Suppl):1-10. PubMed ID: 27820140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease.
    Xin Y; Xu F; Gao Y; Bhatt N; Chamberlain J; Sile S; Hammel S; Holt RJ; Ramanathan S
    Clin Pharmacokinet; 2021 Aug; 60(8):1029-1040. PubMed ID: 33768488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
    Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
    Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.